STIC-Biotech/ChemLib

From: Fredman, Jeffrey
Sent: Monday, January 07, 2002 3:25 PM
To: STIC-Biotech/ChemLib
Cc: Lacourciere, Karen
Subject: FW: Sequence search approval 09/975,123

I Approve.

Jeff Fredman

-----Original Message-----
From: Lacourciere, Karen
Sent: Monday, January 07, 2002 11:24 AM
To: Fredman, Jeffrey
Subject: Sequence search approval 09/975,123

Jeff-
Could you approve this sequence search? Each sequence is an antisense targeted to the same gene. Thank-you!
Karen

Please perform a sequence search in the commercial databases on the following sequences for 09/975,123, Please perform the search as a **length limited search, please limit the length of oligonucleotides to less than 100 nucleotides long:**

13-19, 21, 23-36, and 38-43

Thank-you!

Point of Contact:
Toby Port
Technical Info. Specialist
CM1 1E01 TEL: 308-3534

Karen A. Lacourciere Ph.D.
CM1 11D09 GAU 1635
(703) 308-7523

mailbox 11E12

	TYPE OF SEARCH:	VENDOR/COST(where applic.)
Searcher:	NA Sequences: 38	STN:
Phone:	AA Sequences:	DIALOG:
Location:	Structures:	Questel/Orbit:
		DRI ink:
Clerical:	Patent Family:	WWW/Internet:
Online time:	Other:	Other (specify):

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Name: JANE ZARA — 77512 — Date: 8/12/03

Art Unit: 1635 — Phone Number: 6-5820 — Serial Number: 09/975,123

Mail Box and Bldg/Room Location: 11D03 — Results Format Preferred: PAPER DISK E-MAIL

11E12

If more than one search is submitted, please prioritize searches in order of need. 11E9

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Freier

Inventors (please provide full names): ASG ILGFBP5

Earliest Priority Filing Date: 10/9/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search Seq ID #'s: * 15, 23, 24, 26-30 33-36, 38-43

For Interference + regular data bases.

-Limit ALL TO 100 NT's. ONLY.

Thanks.

* These seq have been searched together before.

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Shelley	NA Sequence #	
Searcher Phone #:	AA Sequence #	
Searcher Location:	Structure #	
Date Searched: 9/12/03	Bibliographic	
Date Completed:	Litigation	
Clerical Prep Time:	Fulltext	
Online Time:	Patent Family	

Set Items Description
S1 [illegible] INSULIN (W) LIKE (W) BIND
S2 11 S1 (S) ANTISENSE OR RIBOZYME?
S3 [illegible] RD (unique items)
S4 14 S2 AND (ANTISENSE OR RIBOZYME?
S5 4 RD (unique items)
S6 [illegible] INSULIN (W) LIKE (W) GROWTH (W) FACTOR (W) BINDING (W) PROTEIN (W) 5
S7 11 S6 (S) (ANTISENSE OR RIBOZYME?)
S8 4 RD (unique items)
S9 41 S6 AND (ANTISENSE OR RIBOZYME?)
S10 [illegible] RD (unique items)
>>>KWIC option is not available in file(s): 41, [illegible], 349

10/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

13216983 BIOSIS NO.: 200100424132
The IGF/IGFBP system in CNS malignancy.
AUTHOR: Zumkeller W(a); Westphal M
AUTHOR ADDRESS: (a)Department of Pediatrics, Martin-Luther-University Halle-Wittenberg, University Hospital, Ernst-Grube-Str. 40, 06097, Halle/Saale: walter.zumkeller@medizin.uni-halle.de**Germany
JOURNAL: Molecular Pathology 54 (4):p227-229 August, 2001
MEDIUM: print
ISSN: 1366-8714
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: Both types of IGF receptor are expressed in gliomas and, in particular, the type I IGF receptor appears to be upregulated in malignant brain tissue. *Antisense* IGF-I receptor mRNA induces an antitumour response, resulting in complete brain tumour regression. Clinical trials for the treatment of brain tumours in humans based on a gene transfer protocol using IGF-I receptor *antisense* are under way. All six IGFBPs are expressed to a variable extent in brain tumours. High concentrations of IGFBP-2 are found in cerebrospinal fluid...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: *antisense* insulin-like growth factor-I receptor messenger RNA...

...*insulin*-*like* *growth* *factor* *binding* *protein*-*5*;

10/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
[illegible]

Castration-induced up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
AUTHOR: Miyake Hideaki; Pollak Michael; Gleave Martin E(a)
AUTHOR ADDRESS: (a)Division of Urology, University of British Columbia, [illegible]
[illegible]

Castration-induced up-regulation of *insulin*-*like* *growth* *factor*

***binding* *protein*-*5* potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.**

ABSTRACT: Although *insulin*-*like* *growth* *factor* *binding* *protein*-*5* (IGFBP-5) has been shown to be implicated in prostate cancer progression, the functional role of IGFBP-5 in progression to androgen-independent growth is largely...

...cells were stably transfected with IGFBP-5 gene, and IGFBP-5-overexpressing LNCaP tumors progressed significantly faster to androgen independence after castration compared with controls. *Antisense* mouse IGFBP-5 oligodeoxynucleotides (ODNs) were then designed that reduced IGFBP-5 expression in Shionogi tumor cells in vitro in a dose-dependent and sequence-specific manner. Growth of Shionogi tumor cells was inhibited by *antisense* IGFBP-5 ODN treatment in a time- and dose-dependent manner, which could be reversed by exogenous IGF-I. However, *antisense* IGFBP-5 ODN treatment had no additive inhibitory effect on Shionogi tumor cell growth when IGF-I activity was neutralized by anti-IGF-I antibody. *Antisense* IGFBP-5 ODN treatment resulted in decreased mitogen-activated protein kinase activity and number of cells in the S + G2-M phases of the cell cycle that directly correlated with reduced proliferation rate of Shionogi tumor cells. Systemic administration of *antisense* IGFBP-5 ODN in mice bearing Shionogi tumors after castration significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors...

...serves to enhance IGF bioactivity and raise the possibility that the response of prostate cancer to androgen withdrawal can be enhanced by strategies, such as *antisense* IGFBP-5 ODN therapy, that target IGF signal transduction.

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor* *binding* *protein*-*5*--...

...human IGFBP-5 gene (human *insulin*-*like* *growth* *factor* *binding* *protein*-*5* gene) (Hominidae)

10/3,K/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

12099757 BIOSIS NO.: 199900394606

Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins.

AUTHOR: Rosen Florence; Pollak Michael(a)

AUTHOR ADDRESS: (a)Lady Davis Institute for Medical Research of the Jewish General Hospital, 3755 Cote Ste. Catheri**Canada

JOURNAL: International Journal of Oncology 15 (3):p589-594 Sept., 1999

ISSN: 1 1-4**

ABSTRACT: [illegible]

...ABSTRACT: [illegible] induced by basal [illegible] IGF-I, and IGF-I analogue with greatly reduced affinity for IGFBPs. Furthermore, we demonstrate that an *antisense* IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-I-stimulated tyrosine phosphorylation of IRS-1 and PI3'-kinase activity. These [illegible]...

11942922 BIOSIS NO.: 199[illegible]9031
Differential expression and localization of IGF-I and IGF binding proteins in inflamed rat colon.
AUTHOR: Beck Joerg M; Mohapatra Niru; Lund P Kay; Eysselein Viktor E; McRoberts James A
AUTHOR ADDRESS: Harbor-UCLA Med. Cent., Div. Gastroenterol., Torrance, CA **USA
JOURNAL: Journal of Receptor and Signal Transduction Research 18 (4-6):p 265-290 July-Nov., 1998
ISSN: 1079-9893
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: were sacrificed at 7 days after induction of colitis. Cryostat sections of colon from TNB-treated and control rats were hybridized with 35 S-labeled *antisense* probes for IGF-1R, IGFBP-3, IGFBP-4 and IGFBP-5. IGF-I mRNA was up-regulated in lamina propria cells, submucosa and smooth muscle...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: ...*insulin*-*like* *growth* *factor* *binding* *protein*-*5*--

10/3,K/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11423292 BIOSIS NO.: 199800209624
Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5* is independent of muscle cell differentiation, sensitive to rapamycin, but insensitive to wortmannin and LY294002.
AUTHOR: Rousse Sophie; Montarras Didier; Pinset Christian; Dubois Catherine (a)
AUTHOR ADDRESS: (a)Inst. Natl. Sante Recherche Med., U.142, Hop. Saint Antoine, 75571 Paris Cedex 12**France
JOURNAL: Endocrinology 139 (4):p1487-1495 April, 1998
ISSN: 0013-7227
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Up-regulation of *insulin*-*like* *growth* *factor* *binding* *protein*-*5* is independent of muscle cell differentiation, sensitive to rapamycin, but insensitive to wortmannin and LY294002.

...ABSTRACT: and modulated by IGF binding proteins (IGFBPs) secreted by the cells. The mouse C2 myoblast cell line stably transfected with a vector [illegible] IGF-II *antisense* RNA was used to show that specific IGFBP expression [illegible] high levels of IGFBP-5 mRNA [illegible]...
DESCRIPTORS:
CHEMICALS & BIOCHEMICALS: [illegible] *protein*-*5*--

10/3,K/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

JOURNAL: [illegible]
CONFERENCE MEETING: 8th Joint Meeting of the European Society for Paediatric Endocrinology and the Lawson Wilkins Society for Pediatric Endocrinology, in collaboration with the Australian Paediatric Endocrine Group, the Japanese Society for Pediatric Endocrinology and the Latin American Society for Paediatric Endocrinology (Stockholm, Sweden June [illegible], 199[illegible]
ISSN: [illegible]
RECORD TYPE: Citation
LANGUAGE: English

MISCELLANEOUS TERMS: ...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-5 *ANTISENSE* OLIGONUCLEOTIDE...
...INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 *ANTISENSE* OLIGONUCLEOTIDE ...

...*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5*;

10/3,K/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10720630 BIOSIS NO.: 199699321775
A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in the antiproliferative action of the antiestrogen ICI 182780.
AUTHOR: Huynh Hung(a); Yang Xiao-Feng; Pollak Michael
AUTHOR ADDRESS: (a)Dep. Med., McGill Univ., 3755 Cote Ste Catherine Rd., Montreal, PQ H3T 1E2**Canada
JOURNAL: Cell Growth & Differentiation 7 (11):p1501-1506 1996
ISSN: 1044-9523
RECORD TYPE: Abstract
LANGUAGE: English

A role for *insulin*-*like* *growth* *factor* *binding* *protein* *5* in the antiproliferative action of the antiestrogen ICI 182780.

...ABSTRACT: mRNA abundance, and increased IGFBP-5 protein accumulation in the conditioned medium. Growth stimulation following estradiol exposure was associated with opposite effects. An IGFBP-5 *antisense* oligodeoxynucleatide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore, this *antisense* oligodeoxynucleotide attenuated both antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth inhibition. These data demonstrate that estradiol down-regulates and ICI up-regulates an...
MISCELLANEOUS TERMS: ...*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN* *5*; *INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN* *1* MRNA

10/3,K/8 (Item 8 from file: 5)
[illegible]

[illegible] BIOSIS NO.: [illegible]
Osteogenic protein-1-mediated insulin-like growth factor gene expression in primary cultures of rat osteoblastic cells.
AUTHOR: [illegible]
AUTHOR ADDRESS: [illegible]

...ABSTRACT: [illegible] IGFBP-4, -5, and -6 mRNA levels [illegible] IGF-I concentration-dependent manner. In addition, coincubation of *antisense* oligonucleotides corresponding to IGF-I [illegible] IGF-II mRNA sequence with IGF-I reduced the IGF-I-induced elevation in alkaline phosphatase activity. The present results...
MISCELLANEOUS TERMS: ...*INSULIN*-*LIKE* *GROWTH* *FACTOR*-*BINDING* *PROTEIN*-*5*;

10/3,K/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

10391965 BIOSIS NO.: 199698004110
***Insulin*-*like* *growth* *factor* *binding* *protein*-*5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**
AUTHOR: James Dayton L; Stewart Claire E H; Rotwein Peter
AUTHOR ADDRESS: Dep. Biochemistry Molecular Biophysics, 660 South Euclid Ave., Box 8231, St. Louis, MO 63110**USA
JOURNAL: Journal of Cell Biology 133 (3):p643-693 1996
ISSN: 0021-9525
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

***Insulin*-*like* *growth* *factor* *binding* *protein*-*5* modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.**

...ABSTRACT: sense myoblasts show enhanced survival in low serum medium, remaining viable for at least four weeks in culture. By contrast, myoblasts expressing the IGFBP-5 *antisense* transcript differentiate prematurely and more extensively than control cells. The inhibition of myogenic differentiation by high level expression of IGFBP-5 could be overcome by...

10/3,K/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

09939075 BIOSIS NO.: 199598049993
Localization of messenger ribonucleic acid for insulin-like growth factor-binding proteins in human skin by in situ hybridization.
AUTHOR: Batch J A(a); Mercuri F A; Edmondson S R; Werther G A
AUTHOR ADDRESS: (a)Cent. Hormone Res., Royal Children's Hosp., Flemington Rd., Parkville, 3052 VIC**Australia
JOURNAL: Journal of Clinical Endocrinology & Metabolism 79 (5):p1444-1449 1994
ISSN: [illegible]
DOCUMENT TYPE: [illegible]
RECORD TYPE: [illegible]
LANGUAGE: [illegible]

...ABSTRACT: [illegible] IGFBPs in human skin, we have used in situ hybridization to localize messenger ribonucleic acid (mRNA) for the six IGFBPs. *Antisense* and sense RNA probes for the IGFBPs [illegible] were prepared, and frozen sections of normal adult human skin [illegible]...
MISCELLANEOUS TERMS: ...*INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*

Increased expression of IGF-binding protein-5 in Duchenne muscular dystrophy (DMD) fibroblasts correlates with the fibroblast-induced downregulation of DMD myoblast growth: an in vitro analysis.

Melone M A; Peluso G; Galderisi U; Petillo O; Petrucci R

Sezione Fisiologia e Biochimica, Seconda Universita di Napoli, School of Medicine, Naples, Italy. marina.melone@unina2.it

Journal of cellular physiology (UNITED STATES) Oct 2000, 185 (1) p143-53, ISSN 0021-9541 Journal Code: 0050222

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... IGFBP-1 in DMD fibroblast-conditioned media by means of specific antibodies, or inhibiting IGFBP-1 gene expression in DMD fibroblasts by means of cells 'antisense', the fibroblast-conditioned media lost inhibitory power over DMD myoblast proliferation. Copyright 2000 Wiley-Liss, Inc.

Descriptors: Fibroblasts--metabolism--ME; *Fibroblasts--pathology--PA; *Insulin*-*Like* *Growth*-*Factor*-*Binding*-*Protein* *5*--biosynthesis --BI; *Muscle, Skeletal--metabolism--ME; *Muscle, Skeletal--pathology--PA; *Muscular Dystrophy, Duchenne--metabolism--ME; *Muscular Dystrophy, Duchenne--pathology--PA

Chemical Name: Culture Media, Conditioned; *Insulin*-*Like* *Growth*-*Factor*-*Binding*-*Protein* *5*

10/3,K/12 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

08764041 96109186 PMID: 8618825

Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells.

Steller M A; Delgado C H; Zou Z

Section of Gynecologic Oncology, National Cancer Institute, Bethesda, MD 20892-1502, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Dec 19 1995, 92 (26) p11970-4, ISSN 0027-8424 Journal Code: 7505876

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... induced mitogenesis was abrogated in a dose-dependent manner by IGF-binding protein 5 (IGFBP-5), which binds to IGF-II and neutralizes it. An 'antisense' oligonucleotide to IGF-II also inhibited the proliferative response to EGF. In addition, prolonged, but not short-term, stimulation with EGF resulted in autophosphorylation of...

Descriptors: Amino Acid Sequence; Base Sequence; *Epidermal Growth Factor --pharmacology--EP; *Insulin-like Growth Factor II--physiology--PH; *Insulin-like Growth Factor II--pharmacology--EP; *Uterine Cervical Neoplasms, *Antisense--pharmacology--EP...; Binding, Competitive--drug effects--EP; Insulin-like Growth Factor I --physiology--PH; Insulin-like Growth Factor I --metabolism--ME; Insulin-like Growth Factor I--pharmacology--EP; *Insulin*-*Like* *Growth*-*Factor*-*Binding*-*Protein* *5*--pharmacology --ED; Kinetics; Mitosis--drug effects--EP; Molecular Sequence Data; Oligodeoxyribonucleotides--pharmacology--EP; RNA, Messenger--metabolism--ME ; Receptor, IGF Type 1--metabolism--ME; Tumor Cells...

Chemical Name: *Epidermal Growth Factor--physiology--EP; *... ; Oligodeoxyribonucleotides; Oligonucleotide, *Antisense*; RNA, Messenger;

[illegible] [illegible] [illegible]

Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries.

El-Roeiy A; Chen X; Roberts V J; Shimasaki S; Ling N; LeRoith D; Roberts C T; Yen S S

Department of Reproductive Medicine, University of California School of Medicine, La Jolla 92093.

Journal of clinical endocrinology and metabolism (UNITED STATES) Jun 1994; [illegible] p1431-40, ISSN 0021-972X Journal Code: 0375362

Support Grant No.: HD-[illegible]; HD; NICHD; HD-07216-11; HD; NICHD; HD-12303-15; HD; NICHD

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... in specific cellular compartments of normal and PCOS human ovaries. Messenger ribonucleic acid (mRNA) was localized by in situ hybridization with specific 35S-labeled human *antisense* RNA probes, and protein was detected by immunohistochemistry using specific antisera. Thecal cells, but not granulosa cells (GC), of small antral follicles (3-6 mm...

...; Growth Factor II--analysis--AN; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*-*Like* *Growth*-*Factor*-*Binding*-*Protein* *5*; Insulin-Like-Growth Factor Binding Protein 6; Middle Age; Ovary--pathology--PA; Polycystic Ovary Syndrome--pathology--PA; RNA Probes; Receptor, IGF Type 1--analysis--AN...

...Chemical Name: Growth-Factor-Binding Protein 4; Insulin-Like Growth Factor-Binding Protein 2; Insulin-Like Growth-Factor Binding Protein 1; Insulin-Like Growth-Factor-Binding Proteins; *Insulin*-*Like* *Growth*-*Factor*-*Binding*-*Protein* *5*; Insulin-Like-Growth-Factor-Binding Protein 6; RNA Probes; RNA, Messenger; Receptor, IGF Type 2; Insulin-Like Growth Factor 1; Insulin-Like Growth Factor II...

10/3,K/14 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

136321287 CA: 136(21)321287w PATENT

Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities

INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft

LOCATION: Den.

ASSIGNEE: Como Biotech Aps

PATENT: PCT International ; WO [illegible] A2 DATE: 20020425

[illegible]

[illegible]

[illegible]

124270541 CA: 124(20)270541s PATENT

Use of antisense nucleic acids/analogs inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders

INVENTOR/AUTHOR: Wainwright, Brett Arthur; Wainwright, Christopher John
LOCATION: Australia
ASSIGNEE: Royal Children's Hospital Research Foundation
PATENT: PCT International ; WO [illegible] A1 DATE: [illegible]
APPLICATION: [illegible]
PAGES: 111 pp. ORDER: [illegible] LANGUAGE: English CLASS: A61K-[illegible]; C12N-[illegible]; C12Q-[illegible]
DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LT; LU; LV; MD; MG; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TT DESIGNATED REGIONAL: KE; MW; SD; SZ; UG; AT; BE; CH ; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

10/3,K/16 (Item 1 from file: 35)
DIALOG(R)File 35:Dissertation Abs Online
(c) 2001 ProQuest Info&Learning. All rts. reserv.

01439558 ORDER NO: AADAA-19933739
***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**
Author: JAMES, PAYTON LEIGH
Degree: PH.D.
Year: 1995
Corporate Source/Institution: WASHINGTON UNIVERSITY (0252)
Source: VOLUME 56/06-B OF DISSERTATION ABSTRACTS INTERNATIONAL. PAGE 2987. 168 PAGES

***INSULIN*-*LIKE* *GROWTH* *FACTOR* *BINDING* *PROTEIN*-*5* INHIBITS MYOGENIC DIFFERENTIATION THROUGH AN IGF-DEPENDENT PROCESS**

...dependent manner.
Stable transfectants of the C2 cell line were established which constitutively express the coding sequence of IGFBP-5 in either the sense or *antisense* orientation to determine the function of this protein during myogenic differentiation. Forced expression of the *antisense* transcripts caused rapid differentiation as assessed by myotube formation, creatine kinase activity, and the production of myosin heavy chain and the muscle-specific transcription factor...

10/3,K/17 (Item 1 from file: 159)
DIALOG(R)File 159:Cancerlit
(c) format only 2002 Dialog Corporation. All rts. reserv.

02322558 PMID: 97604744
Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5* (IGFBP-5) (Meeting abstract).
[illegible]
Document Type: MEETING ABSTRACT
Language: ENGLISH
Main Citation Owner: NLM
Record Type: Completed

Antiproliferative effects of ICI 182780 are partly mediated by upregulation of *insulin*-*like* *growth* *factor* *binding* *protein* *5*

and antiestrogen-induced growth inhibition. These results indicate that ICI [illegible] enhances [illegible] [illegible] by [illegible] an IGFBP-3...
Chemical Name: ICI [illegible]; Estradiol; Estrogen Antagonists; *Insulin-Like Growth-Factor-Binding-Protein 3*; RNA, Messenger

[illegible]

5/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

[illegible] BIOSIS NO.: [illegible]
Mesenchymal-epithelial transition in the developing metanephric kidney: Gene expression study by differential display.
AUTHOR: Plisov Sergei Yu[a]; Ivanov Sergey V; Yoshino Kiyoshi; Dove Lee F; Plisova Tatiana M; Highsmith Kathleen S; Karavanova Irina; Lerman Michael; Perantoni Alan O
AUTHOR ADDRESS: [a]National Cancer Institute-FCRDC, Bldg. 538, Room 205E, Frederick, MD, 21702-1201**USA
JOURNAL: Genesis The Journal of Genetics and Development 27 (1):p22-31 May, 2000
MEDIUM: print
ISSN: 1526-954X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: proteins (SH3-domain binding protein, G-protein-coupled receptor, Ser-Thr protein kinase), cell adhesion molecules (syndecan-4, integrin-beta1), and also gene33, H19, SM20, *IGFBP5*, MAMA receptor, lectin, keratin, beta-tubulin, calreticulin, GRP78, ERp72, MnSoD, thioredoxin, and others. Some have previously been associated with kidney development and serve as good controls for expected changes, while most have not been linked with kidney epithelial cell differentiation. Using thin sections of embryonic kidney and labeled *antisense* RNA probes, we applied RNA hybridization to confirm the results of DD and related the expression of these genes to specific cell lineages of the...

5/3,K/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

11428292 BIOSIS NO.: 199800209624
Up-regulation of insulin-like growth factor binding protein-5 is independent of muscle cell differentiation, sensitive to rapamycin, but insensitive to wortmannin and LY294002.
AUTHOR: [illegible]
AUTHOR ADDRESS: [illegible]
[illegible]
ISSN: [illegible]
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: [illegible]

5/3,K/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

136321287 CA: 136(21)321287w PATENT
Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities
INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Tolr
LOCATION: Den.
ASSIGNEE: Ocmc Biotech Aps
PATENT: PCT International ; WO 200231455 A2 DATE: 20020418
APPLICATION: WO 2001DK695 (20011019) *DK 2000001521 (20001020) *US PV241840 (20001020)
PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/435A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EE; EE; ES; FI; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

5/3,K/4 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134125934 CA: 134(10)125934z PATENT
IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors
INVENTOR(AUTHOR): Gleave, Martin
LOCATION: Can.,
ASSIGNEE: The University of British Columbia; Miyake, Hideaki
PATENT: PCT International ; WO 200105435 A2 DATE: 20010125
APPLICATION: WO 2000CA853 (20000719) *US PV144495 (19990719)
PAGES: 45 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

[illegible]

3/3,K/1 (Item 1 from file: 5)

[illegible] BIOSIS NO.: [illegible]

Mesenchymal-epithelial transition in the developing metanephric kidney: Gene expression study by differential display.

AUTHOR: Elisov Sergei Y (a); Ivanov Sergey V; Yoshino Kiyoshi; Dove Lee F; Plisova Tatiana M; Higinbotham Kathleen G; Karavanova Irina; Lerman Michael; Perantoni Alan O
AUTHOR ADDRESS: (a) National Cancer Institute-FCRDC, Bldg. 538, Room 205F, Frederick, MD, 21702-1201**USA

JOURNAL: Genesis The Journal of Genetics and Development 27 (1):p22-31 May, 2000
MEDIUM: print
ISSN: 1526-954X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

...ABSTRACT: proteins (SH3-domain binding protein, G-protein-coupled receptor, Ser-Thr protein kinase), cell adhesion molecules (syndecan-4, integrin-beta1), and also gene33, H19, SM20, *IGFBP5*, MAMA receptor, lectin, keratin, beta-tubulin, calreticulin, GRP78, ERp72, MnSoD, thioredoxin, and others. Some have previously been associated with kidney development and serve as good controls for expected changes, while most have not been linked with kidney epithelial cell differentiation. Using thin sections of embryonic kidney and labeled *antisense* RNA probes, we applied RNA hybridization to confirm the results of DD and related the expression of these genes to specific cell lineages of the...

3/3,K/2 (Item 2 from file: 5)

11428292 BIOSIS NO.: 199800209624

Up-regulation of insulin-like growth factor binding protein-5 is independent of muscle cell differentiation, sensitive to rapamycin, but insensitive to wortmannin and LY294002.

AUTHOR: Rousse Sophie; Montarras Didier; Pinset Christian; Dubois Catherine (a)
AUTHOR ADDRESS: [illegible]

JOURNAL: [illegible] April, [illegible]
ISSN: [illegible]
DOCUMENT TYPE: [illegible]
RECORD TYPE: [illegible]
LANGUAGE: [illegible]

...ABSTRACT: [illegible] IGFBPs [illegible] secreted by the cells. [illegible] stably transfected with a vector [illegible] IGF-II [illegible] RNA [illegible] IGFBP [illegible] IGFBP- [illegible]

3/3,K/3 (Item 1 from file: 399)

134125934 CA: 134(10)125934z PATENT

IGFBP-5 antisense oligodeoxynucleotide therapy for hormone-regulated tumors

INVENTOR(S): [illegible]

LOCATION: [illegible]

ASSIGNEE: [illegible]

PATENT: [illegible]

APPLICATION: [illegible]

PAGES: [illegible]

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM [DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

[illegible] examin[illegible]
[illegible] unique items
?show files;[illegible]
File [illegible]:[illegible] Previews [illegible] Aug W[illegible]
[illegible] BIOSIS
File [illegible]:NTIS 1964-[illegible] Aug W[illegible]
[illegible] NTIS, Intl Cpyrght All Rights Res
File [illegible]:[illegible]Compendex[illegible] 19[illegible] Aug W[illegible]
[illegible] Engineering Info. Inc.
File 34:SciSearch(R) Cited Ref Sci 19[illegible] Aug W3
[illegible] Inst for Sci Info
File [illegible]:Inside Conferences 199[illegible]-200[illegible]/Aug W2
[illegible] BLDSC all rts. reserv.
File [illegible]:ELSEVIER BIOBASE 1994-[illegible]/Aug W[illegible]
[illegible] Elsevier Science B.V.
File [illegible]:EMBASE 1974-2002/Aug W2
(c) 2002 Elsevier Science B.V.
File [illegible]:Life Sciences Collection 198[illegible]-2002/Jul
(c) [illegible] Cambridge Sci Abs
File 94:JICST-EPlus 1985-2002/Jun W[illegible]
(c)2002 Japan Science and Tech Corp(JST)
File 98:General Sci Abs/Full-Text 1984-2002/Jun
(c) 2002 The HW Wilson Co.
File 99:Wilson Appl. Sci. & Tech Abs 1983-2002/Jun
(c) 2002 The HW Wilson Co.
File 135:NewsRx Weekly Reports 1995-2002/Aug W1
(c) 2002 NewsRx
File 143:Biol. & Agric. Index 1983-2002/Jun
(c) 2002 The HW Wilson Co
File 144:Pascal 197[illegible]-20[illegible]/Aug W2
(c) 2002 INIST/CNRS
File 155:MEDLINE(R) 1966-2002/Aug W2
File 172:EMBASE Alert 2002/Aug W2
(c) 2002 Elsevier Science B.V.
File 266:FEDRIP 200[illegible]/Jun
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315:ChemEng & Biotec Abs 1970-2002/Jun
(c) 2002 DECHEMA
File 357:Derwent Biotech Res. 1982-2002/June W1
(c) 2002 Thomson Derwent & ISI
File 358:Current BioTech Abs 1983-2001/Oct
(c) 2001 DECHEMA
File 369:New Scientist 1994-2002/Jul W2
(c) 2002 Reed Business Information Ltd.
File 370:Science 19[illegible]6-1999/Jul W3
(c) 1999 AAAS
File 399:CA SEARCH(R) 1967-2002/UD=13707
(c) 2002 AMERICAN CHEMICAL SOCIETY
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
[illegible] Inst for Sci Info
[illegible] May
[illegible]
[illegible]
[illegible]
[illegible] CAB [illegible]
File [illegible]:Env.Bib. 19[illegible]-[illegible]/Jun
[illegible] Internl Academy at Santa Barbara
File [illegible]:Conference Papers Index 197[illegible]-[illegible] Jul
[illegible] Cambridge Sci Abs
[illegible]
[illegible]
[illegible]

Set	Items	Description
S1	536	IGFBP5 OR (IGF (W) BP5)
S2	13	S1 (S) (ANTISENSE OR RIBOZYME?)
S3	3	RD (unique items)
S4	14	S1 AND (ANTISENSE OR RIBOZYME?)
S5	4	RD (unique items)
S6	1907	INSULIN (W) LIKE (W) GROWTH (W) FACTOR (W) BINDING (W) PROTEIN (W) 5
S7	11	S6 (S) (ANTISENSE OR RIBOZYME?)
S8	4	RD (unique items)
S9	42	S6 AND (ANTISENSE OR RIBOZYME?)
S10	17	RD (unique items)

[illegible]

8/3,K/1 (Item 1 from file: 5)
[illegible]
(c) 2002 BIOSIS. All rts. reserv.

12879e11 BIOSIS NO.: [illegible]
Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
AUTHOR: Miyake Hideaki; Pollak Michael; Gleave Martin E(a)
AUTHOR ADDRESS: (a)Division of Urology, University of British Columbia, D-3, 2733 Heather Street, Vancouver, BC, V5Z 3J5**Canada
JOURNAL: Cancer Research 60 (11):p3068-3064 June 1, 2000
MEDIUM: print
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ABSTRACT: Although *insulin*-*like* *growth* *factor* *binding* *protein*-*5* (IGFBP-5) has been shown to be implicated in prostate cancer progression, the functional role of IGFBP-5 in progression to androgen-independence remains largely...
...cells were stably transfected with IGFBP-5 gene, and IGFBP-5-overexpressing LNCaP tumors progressed significantly faster to androgen independence after castration compared with controls. *Antisense* mouse IGFBP-5 oligodeoxynucleotides (ODNs) were then designed that reduced IGFBP-5 expression in Shionogi tumor cells in vitro in a dose-dependent and sequence-specific manner. Growth of Shionogi tumor cells was inhibited by *antisense* IGFBP-5 ODN treatment in a time- and dose-dependent manner, which could be reversed by exogenous IGF-I. However, *antisense* IGFBP-5 ODN treatment had no additive inhibitory effect on Shionogi tumor cell growth when IGF-I activity was neutralized by anti-IGF-I antibody. *Antisense* IGFBP-5 ODN treatment resulted in decreased mitogen-activated protein kinase activity and number of cells in the S + G2-M phases of the cell cycle that directly correlated with reduced proliferation rate of Shionogi tumor cells. Systemic [illegible]
...[illegible]
...response of prostate cancer [illegible] androgen withdrawal can be enhanced by strategies, such as *antisense* IGFBP-5 ODN therapy, that target IGF signal transduction.

8/3,K/2 (Item 1 from file: 98)
[illegible]

differentiation through an insulin like growth factor-dependent mechanism.

James, Payt[illegible]
Stewart, [illegible] E. H; Rotwein, Peter
The Journal of Cell Biology (J Cell Biol) v. 13[illegible] no[illegible] (May 1996) p. 683-93
SPECIAL FEATURES: [illegible] ISSN: [illegible]
LANGUAGE: English
COUNTRY OF PUBLICATION: United States

ABSTRACT: The function of *insulin*-*like* *growth* *factor* *binding* *protein* *5* (IGFBP-5) in myogenesis, a process stimulated by IGFs, was studied using C2 myoblasts. Compared with vector-transfected control cells, C2 myoblasts expressing an IGFBP...

...extracellular matrix during proliferation and subsequently did not differentiate normally. In contrast, differentiation was premature and more extensive in the presence of an IGFBP-5 *antisense* transcript. The inhibitory effects of high IGFBP-5 expression were overcome by exogenous IGFs. These findings are in agreement with a model in which IGFBP...

8/3,K/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

136321287 CA: 136(21)321287w PATENT
Use of pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase, for diagnosis and treatment of fetal abnormalities
INVENTOR(AUTHOR): Oxvig, Claus; Overgaard, Michael Toft
LOCATION: Den.
ASSIGNEE: Como Biotech Aps
PATENT: PCT International ; WO 200232953 A2 DATE: 20020425
APPLICATION: WO 2001DK695 (20011019) *DK 20001571 (20001020) *US PV241840 (20001020)
PAGES: 113 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/435A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; CZ; DE; DE; DK; DK; DM; DZ; EC; EE; EE; ES; FI; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE ; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3,K/4 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

124270541 CA: 124(20)270541s PATENT
Use of antisense nucleic acids/analogs inhibiting growth factor-mediated cell proliferation for treatment of proliferative and/or inflammatory skin disorders
[illegible]
LOCATION: Australia
ASSIGNEE: Royal Children's Hospital Research Foundation
PATENT: PCT International ; WO [illegible] A1 DATE: [illegible]
APPLICATION: [illegible]
PAGES: 115 pp. CODEN: [illegible] LANGUAGE: English CLASS: A61K-031/[illegible]A; [illegible]
[illegible]